Orano Med Expands Texas R&D Hub, Accelerating Radioligand Therapies for Cancer
Plano, Texas – Orano Med, a specialized subsidiary of the global Orano Group focused on developing innovative radioligand therapies in oncology, today, June 27, 2025, marked a significant milestone with the official inauguration of the expanded facilities at its main U.S. Research and Development Center located here. The expansion, representing a substantial investment exceeding $5…